Free Trial

Viridian Therapeutics (VRDN) Competitors

Viridian Therapeutics logo
$24.21 +1.20 (+5.22%)
Closing price 04:00 PM Eastern
Extended Trading
$24.20 -0.01 (-0.04%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VRDN vs. RDNT, BTSG, SHC, OPCH, WGS, PRVA, HTFL, VCYT, CON, and SGRY

Should you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Option Care Health (OPCH), GeneDx (WGS), Privia Health Group (PRVA), Heartflow (HTFL), Veracyte (VCYT), Concentra Group Holdings Parent (CON), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry.

Viridian Therapeutics vs. Its Competitors

Viridian Therapeutics (NASDAQ:VRDN) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viridian Therapeutics$300K6,590.77-$269.95M-$3.83-6.32
RadNet$1.83B3.23$2.79M-$0.20-384.65

Viridian Therapeutics presently has a consensus price target of $34.88, suggesting a potential upside of 44.05%. RadNet has a consensus price target of $76.80, suggesting a potential downside of 0.17%. Given Viridian Therapeutics' higher possible upside, equities analysts plainly believe Viridian Therapeutics is more favorable than RadNet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viridian Therapeutics
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.70
RadNet
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
3 Strong Buy rating(s)
3.13

RadNet has a net margin of -0.78% compared to Viridian Therapeutics' net margin of -112,806.88%. RadNet's return on equity of 2.41% beat Viridian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Viridian Therapeutics-112,806.88% -78.95% -49.91%
RadNet -0.78%2.41%0.82%

77.9% of RadNet shares are owned by institutional investors. 1.6% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 5.6% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, RadNet had 3 more articles in the media than Viridian Therapeutics. MarketBeat recorded 5 mentions for RadNet and 2 mentions for Viridian Therapeutics. RadNet's average media sentiment score of 1.28 beat Viridian Therapeutics' score of 0.70 indicating that RadNet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viridian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
RadNet
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Viridian Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, RadNet has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Summary

RadNet beats Viridian Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRDN vs. The Competition

MetricViridian TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.88B$3.40B$6.11B$10.51B
Dividend YieldN/A2.29%5.73%4.81%
P/E Ratio-6.3222.4484.5227.09
Price / Sales6,590.77484.29609.45131.82
Price / CashN/A46.5937.1661.22
Price / Book3.9810.4112.246.52
Net Income-$269.95M-$52.47M$3.32B$276.75M
7 Day Performance15.34%2.30%0.76%0.92%
1 Month Performance30.02%14.45%8.03%4.20%
1 Year Performance-0.21%12.90%71.13%37.86%

Viridian Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRDN
Viridian Therapeutics
2.0897 of 5 stars
$24.21
+5.2%
$34.88
+44.1%
-3.3%$1.88B$300K-6.3250News Coverage
Positive News
RDNT
RadNet
3.2703 of 5 stars
$71.72
+1.6%
$76.80
+7.1%
+10.0%$5.43B$1.83B-358.5811,021News Coverage
Positive News
Analyst Upgrade
BTSG
BrightSpring Health Services
2.9017 of 5 stars
$29.48
+3.9%
$30.50
+3.5%
+85.7%$5.02B$11.27B95.1035,000Analyst Forecast
SHC
Sotera Health
2.8986 of 5 stars
$15.67
+2.1%
$17.20
+9.8%
+2.6%$4.36B$1.10B195.903,000
OPCH
Option Care Health
4.8398 of 5 stars
$26.67
-0.1%
$35.11
+31.7%
-12.3%$4.33B$5.00B21.348,088Positive News
Analyst Forecast
WGS
GeneDx
2.7409 of 5 stars
$120.87
-0.7%
$104.13
-13.9%
+94.8%$3.50B$305.45M2,417.401,200
PRVA
Privia Health Group
2.7708 of 5 stars
$24.14
+0.2%
$28.91
+19.8%
+41.0%$2.96B$1.74B219.471,140
HTFL
Heartflow
N/A$33.22
-0.7%
$36.60
+10.2%
N/A$2.79BN/A0.00699Positive News
VCYT
Veracyte
3.7938 of 5 stars
$34.09
-2.0%
$40.90
+20.0%
+3.1%$2.74B$445.76M103.31790News Coverage
CON
Concentra Group Holdings Parent
2.8982 of 5 stars
$20.17
-0.7%
$27.75
+37.6%
-8.2%$2.60B$1.90B16.9511,250
SGRY
Surgery Partners
3.4996 of 5 stars
$19.79
+0.3%
$32.00
+61.7%
-35.3%$2.53B$3.11B-13.8415,000

Related Companies and Tools


This page (NASDAQ:VRDN) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners